文献速递产科母胎医学

早孕期风险与阿司匹林依从性对早产型子痫前期预防的联合影响

Combined impact of first-trimester risk and aspirin adherence on preterm preeclampsia prevention.
PubMed 文献 · Am J Obstet Gynecol · 2026-02-16

本研究合并两个队列共51024例单胎妊娠数据,在孕11+0至13+6周用FMF竞争风险模型筛查早产型子痫前期风险,并通过蒙特卡洛模拟评估阿司匹林依从性与基线风险对预防效果的联合影响。结果显示阿司匹林预防效果随依从性升高而增强,完全依从时RR为0.25(95%CI 0.09-0.66),50%依从时RR为0.70(95%CI 0.58-0.98)。决策曲线分析表明,基于FMF模型的目标性筛查与治疗策略净获益优于普遍用药。

要点

  • 阿司匹林预防早产型子痫前期的效果高度依赖依从性与基线风险,低风险人群绝对获益可忽略。
  • 决策曲线分析支持用FMF模型进行目标性筛查与治疗,优于对所有孕妇普遍给予阿司匹林。
  • 高风险且依从性好时获益最大,完全依从RR为0.25(95%CI 0.09-0.66)。

核心结论

  • 阿司匹林对高风险女性预防早产型子痫前期高度有效,但其效果取决于预测风险和阿司匹林依从性。
  • 低风险人群中阿司匹林治疗的绝对获益可忽略。
  • 采用FMF模型的目标性筛查与治疗策略可在最大化临床获益的同时减少不必要的治疗。

研究设计与样本

  • 合并Aspirin for Evidence-based Preeclampsia Prevention和Screening Program for Preeclampsia两个队列的数据。
  • 纳入单胎妊娠且分娩孕周≥24周的孕妇,共51024例。
  • 所有妊娠在孕11+0至13+6周采用FMF竞争风险模型筛查早产型子痫前期风险。
  • 运用蒙特卡洛模拟对阿司匹林依从性和基线风险分布建模,评估四种依从性场景下的相对风险、绝对风险降低和需治疗人数。
  • 四种依从性场景为:完全依从100%、基于试验的意向治疗、50%依从、以及依从性与预测风险正相关的可变依从(ρ=0.4)。

主要发现

  • 在固定依从性场景中,完全依从时预防效果最强,RR为0.25(95%CI 0.09-0.66)。
  • 50%依从时预防效果最弱,RR为0.70(95%CI 0.58-0.98)。
  • 可变依从场景下,相对风险随基线风险呈非线性下降,高风险女性中接近符合方案效果,低风险女性中接近无效。
  • 绝对风险降低和需治疗人数高度依赖预测风险:在1/50至1/100风险水平,高依从性时NNT为73至146,50%依从时NNT为161至321。
  • 在更低风险水平,即使高依从性,NNT也超过数千。

关键数值与推荐

  • 早产型子痫前期筛查采用FMF竞争风险模型,结合母体特征、平均动脉压、子宫动脉搏动指数和血清胎盘生长因子。
  • 完全依从时RR为0.25(95%CI 0.09-0.66);50%依从时RR为0.70(95%CI 0.58-0.98)。
  • 在1/50至1/100风险水平,高依从性NNT为73至146,50%依从NNT为161至321。
  • 可变依从性与预测风险的相关系数设为ρ=0.4。

临床怎么用

  • 临床上应优先识别早产型子痫前期高风险孕妇,并重点提高其阿司匹林依从性以获得最大预防效果。
  • 对低风险孕妇常规给予阿司匹林预防早产型子痫前期获益极小,可避免不必要的干预。
  • 推荐采用FMF竞争风险模型进行早孕期筛查,对筛查阳性者实施目标性阿司匹林预防策略。

局限性

  • 阿司匹林依从性和基线风险分布通过蒙特卡洛模拟建模得出,并非全部来自直接观察数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aspirin prevents preterm preeclampsia in high-risk pregnancies, but the extent to which its effectiveness depends on adherence and baseline risk remains uncertain. OBJECTIVE: To evaluate how first-trimester preeclampsia risk and aspirin adherence jointly influence aspirin's preventive effect, and to assess the potential benefits and harms of targeted versus universal prophylaxis. STUDY DESIGN: We combined data from the Aspirin for Evidence-based Preeclampsia Prevention and the Screening Program for Preeclampsia cohorts, including singleton pregnancies delivering at ≥24 weeks. All pregnancies were screened for preterm preeclampsia at 11+0 to 13+6 weeks using the Fetal Medicine Foundation competing risks model, which combines maternal characteristics, mean arterial pressure, uterine artery pulsatility index, and serum placental growth factor. Aspirin adherence and baseline risk distributions were modeled using Monte Carlo simulations to estimate relative risk, absolute risk reduction, and number needed to treat under 4 adherence scenarios: full (100%), trial-based (intention-to-treat), 50%, and variable adherence positively correlated with predicted risk (ρ=0.4). Decision-curve analysis assessed net benefit across risk thresholds. RESULTS: Simulations informed by 51,024 pregnancies indicated that aspirin's preventive effect varied substantially with adherence. In fixed-adherence scenarios, the strongest effect occurred with full adherence (relative risk 0.25, 95% confidence interval 0.09-0.66) and the weakest with 50% adherence (relative risk 0.70, 95% confidence interval 0.58-0.98). Under variable adherence, relative risk decreased nonlinearly with baseline risk, approaching the per-protocol effect in high-risk women but near null in low-risk women. Absolute risk reduction and number needed to treat were highly dependent on predicted risk: at 1 in 50 to 1 in 100 risks, number needed to treat ranged from 73 to 146 with high adherence and 161 to 321 with 50% adherence, whereas at lower risks, numbers needed to treat exceeded several thousand even with high adherence. Decision-curve analysis indicated that targeted prophylaxis using the Fetal Medicine Foundation model provided greater net benefit than universal treatment, primarily by avoiding unnecessary interventions. CONCLUSION: Aspirin is highly effective for preventing preterm preeclampsia in women at increased risk, but its effect depends on predicted risk and adherence. The absolute benefit of treatment is negligible in low-risk populations. A targeted screen-and-treat strategy using the Fetal Medicine Foundation model maximizes clinical benefit while minimizing unnecessary treatment.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Rolnik, Tan, Syngelaki, et al. Combined impact of first-trimester risk and aspirin adherence on preterm preeclampsia prevention. Am J Obstet Gynecol. 2026. PMID: 41707896. doi:10.1016/j.ajog.2026.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。